TRGV2

Across TCGA pan-cancer cohorts, TRGV2 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated TRGV2 data layer compared with 2 for mutation status.

The strongest signal is observed in uveal melanoma (UVM), where higher TRGV2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TRGV2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and CESC show a favorable association.

UVM, SKCM, and CESC are the cancer types where TRGV2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Tertile	All	0.328	0.736	<.001	114	view →
SKCM	OS	Tertile	All	0.453	0.242	<.001	113	view →
CESC	OS	Tertile	All	0.960	0.798	<.001	76	view →
MESO	DFS	Tertile	II,III,IV	0.477	0.216	<.001	74	view →
HNSC	DFS	Tertile	All	0.741	0.611	<.001	63	view →
LIHC	DFS	Median	All	0.420	0.201	.001	37	view →
BLCA	OS	Median	III,IV	0.743	0.619	.009	29	view →
LGG	OS	Median	All	0.842	0.929	<.001	27	view →
STAD	OS	Tertile	II,III,IV	0.533	0.283	.007	25	view →
CHOL	DFS	Median	II,III,IV	0.608	0.120	.008	18	view →
THCA	DFS	Median	III,IV	0.843	0.578	.008	17	view →
BRCA	DFS	Median	All	0.589	0.469	.012	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

TRGV2–UVM (OS)

Open the UVM breakdown →